← Back to Search

Nonsteroidal Anti-inflammatory Drug

Arm 1: I-ASA 100mg, then C-ASA 162mg tablet for Obstructive Pulmonary Disease

Phase 1
Waitlist Available
Research Sponsored by Vectura, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720
Awards & highlights

Study Summary

This trial compares safety, effectiveness, and side effects of two forms of aspirin given to adults with lung issues.

Eligible Conditions
  • Obstructive Pulmonary Disease
  • Restrictive Lung Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720
This trial's timeline: 3 weeks for screening, Varies for treatment, and minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the ASA plasma concentration versus time curve (AUC0-inf)
Area under the ASA plasma concentration versus time curve (AUC0-t)
Peak plasma concentration of ASA (Cmax)
Secondary outcome measures
Area under the plasma concentration versus time curve (AUC0-inf) of SA.
Area under the plasma concentration versus time curve (AUC0-t) of SA.
Incidence and frequency of adverse events
+14 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: C-ASA 162mg tablet, then I-ASA 100mgExperimental Treatment2 Interventions
Treatment A: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)tablets. Treatment B: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.
Group II: Arm 1: I-ASA 100mg, then C-ASA 162mg tabletExperimental Treatment2 Interventions
Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI. Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA) tablets.

Find a Location

Who is running the clinical trial?

Vectura, Inc.Lead Sponsor
1 Previous Clinical Trials
86 Total Patients Enrolled
Syneos HealthOTHER
172 Previous Clinical Trials
68,199 Total Patients Enrolled
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top